{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:29:12Z","timestamp":1793834952535,"version":"4.6.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oral squamous cell carcinoma (OSCC) is an aggressive malignancy characterized by poor prognosis, largely attributable to cancer stem cell (CSC) persistence and ferroptosis resistance. However, the molecular mechanisms that coordinately regulate stemness maintenance and ferroptosis suppression in OSCC remain insufficiently characterized. In this study, KIF20A was identified as significantly overexpressed in OSCC and strongly correlated with adverse clinical outcomes. An integrative approach identified DHX9 as a candidate interactor of KIF20A. Mechanistic investigations revealed that KIF20A regulates DHX9 nucleocytoplasmic distribution and inhibits TRIM21-mediated K48-linked polyubiquitination at DHX9-K755, thereby preventing its proteasomal degradation and enhancing protein stability. Elevated DHX9 enhanced SOX2 mRNA stability, leading to upregulation of SOX2, a central regulator of both CSC maintenance and ferroptosis resistance. Functionally, KIF20A promoted CSC phenotypes, inhibited ferroptosis in vitro and in vivo, and activated the PI3K\/AKT signaling pathway. Notably, treatment with ENMD-2076 (identified through Connectivity Map analysis) significantly reduced KIF20A expression, attenuated CSC characteristics, augmented cisplatin sensitivity, and exerted marked antitumor activity. These findings elucidate a novel KIF20A-DHX9-SOX2 regulatory axis that simultaneously governs CSC maintenance and ferroptosis evasion in OSCC. Targeting KIF20A, either as a monotherapy or in combination with chemotherapy, may offer a promising strategy to improve therapeutic outcomes in OSCC.<\/jats:p>","DOI":"10.1038\/s41419-026-08467-w","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:05:01Z","timestamp":1770833101000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["KIF20A inhibits TRIM21-dependent ubiquitination of DHX9 to boost SOX2 stability, enhancing OSCC stemness and ferroptosis resistance"],"prefix":"10.1038","volume":"17","author":[{"given":"Ziyun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingjie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanpeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dade","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2354-5321","authenticated-orcid":false,"given":"Yongguang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiqing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9146-3478","authenticated-orcid":false,"given":"Li","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-9498","authenticated-orcid":false,"given":"Yiqun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"8467_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1007429","volume":"13","author":"H He","year":"2022","unstructured":"He H, Liang L, Huang J, Jiang S, Liu Y, Sun X, et al. KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma. Front Pharmacol. 2022;13:1007429.","journal-title":"Front Pharmacol"},{"key":"8467_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"8467_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13046-020-01602-1","volume":"39","author":"MX Cao","year":"2020","unstructured":"Cao MX, Zhang WL, Yu XH, Wu JS, Qiao XW, Huang MC, et al. Interplay between cancer cells and M2 macrophages is necessary for miR-550a-3-5p down-regulation-mediated HPV-positive OSCC progression. J Exp Clin Cancer Res. 2020;39:102.","journal-title":"J Exp Clin Cancer Res"},{"key":"8467_CR4","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.oooo.2016.08.021","volume":"123","author":"PM Speight","year":"2017","unstructured":"Speight PM, Epstein J, Kujan O, Lingen MW, Nagao T, Ranganathan K, et al. Screening for oral cancer-a perspective from the Global Oral Cancer Forum. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123:680\u20137.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"8467_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115212","volume":"204","author":"H Marles","year":"2022","unstructured":"Marles H, Biddle A. Cancer stem cell plasticity and its implications in the development of new clinical approaches for oral squamous cell carcinoma. Biochem Pharmacol. 2022;204:115212.","journal-title":"Biochem Pharmacol"},{"key":"8467_CR6","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"8467_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41586-024-08285-0","volume":"637","author":"X Zhuang","year":"2025","unstructured":"Zhuang X, Wang Q, Joost S, Ferrena A, Humphreys DT, Li Z, et al. Ageing limits stemness and tumorigenesis by reprogramming iron homeostasis. Nature. 2025;637:184\u201394.","journal-title":"Nature"},{"key":"8467_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1182\/blood.2024024072","volume":"144","author":"N Hassan","year":"2024","unstructured":"Hassan N, Yi H, Malik B, Gaspard-Boulinc L, Samaraweera SE, Casolari DA, et al. Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4\/HOXA9-dependent AML. Blood. 2024;144:84\u201398.","journal-title":"Blood"},{"key":"8467_CR9","doi-asserted-by":"publisher","first-page":"e37831","DOI":"10.1097\/MD.0000000000037831","volume":"103","author":"J Zhang","year":"2024","unstructured":"Zhang J, Di Y, Zhang B, Li T, Li D, Zhang H. CDK1 and CCNA2 play important roles in oral squamous cell carcinoma. Medicine. 2024;103:e37831.","journal-title":"Medicine"},{"key":"8467_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.993820","volume":"10","author":"D Sun","year":"2022","unstructured":"Sun D, Zhang H, Zhang C, Wang L. An evaluation of KIF20A as a prognostic factor and therapeutic target for lung adenocarcinoma using integrated bioinformatics analysis. Front Bioeng Biotechnol. 2022;10:993820.","journal-title":"Front Bioeng Biotechnol"},{"key":"8467_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.662840","volume":"11","author":"C Galeaz","year":"2021","unstructured":"Galeaz C, Totis C, Bisio A. Radiation resistance: a matter of transcription factors. Front Oncol. 2021;11:662840.","journal-title":"Front Oncol"},{"key":"8467_CR12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.bjc.6606052","volume":"104","author":"K Imai","year":"2011","unstructured":"Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, et al. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer. Br J Cancer. 2011;104:300\u20137.","journal-title":"Br J Cancer"},{"key":"8467_CR13","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/ijc.30510","volume":"140","author":"M Miyazawa","year":"2017","unstructured":"Miyazawa M, Katsuda M, Maguchi H, Katanuma A, Ishii H, Ozaka M, et al. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Int J Cancer. 2017;140:973\u201382.","journal-title":"Int J Cancer"},{"key":"8467_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3892\/ijo.2020.5060","volume":"57","author":"M Nakamura","year":"2020","unstructured":"Nakamura M, Takano A, Thang PM, Tsevegjav B, Zhu M, Yokose T, et al. Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer. Int J Oncol. 2020;57:277\u201388.","journal-title":"Int J Oncol"},{"key":"8467_CR15","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/ddr.22061","volume":"84","author":"Q Wang","year":"2023","unstructured":"Wang Q, Wu H, Wu Q, Zhong S. Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K\/AKT pathway. Drug Dev Res. 2023;84:907\u201321.","journal-title":"Drug Dev Res"},{"key":"8467_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jgr.2023.06.008","volume":"48","author":"R Zhang","year":"2024","unstructured":"Zhang R, Li L, Li H, Bai H, Suo Y, Cui J, et al. Ginsenoside 20(S)-Rg3 reduces KIF20A expression and promotes CDC25A proteasomal degradation in epithelial ovarian cancer. J Ginseng Res. 2024;48:40\u201351.","journal-title":"J Ginseng Res"},{"key":"8467_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1469827","volume":"15","author":"Z Su","year":"2024","unstructured":"Su Z, Zhong Y, He Y, You L, Xin F, Wang L, et al. Bulk- and single cell-RNA sequencing reveal KIF20A as a key driver of hepatocellular carcinoma progression and immune evasion. Front Immunol. 2024;15:1469827.","journal-title":"Front Immunol"},{"key":"8467_CR18","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1016\/j.apsb.2022.05.021","volume":"12","author":"J Wei","year":"2022","unstructured":"Wei J, Chen X, Li Y, Li R, Bao K, Liao L, et al. Cucurbitacin B-induced G2\/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway. Acta Pharm Sin B. 2022;12:3861\u201376.","journal-title":"Acta Pharm Sin B"},{"key":"8467_CR19","doi-asserted-by":"publisher","first-page":"e18040","DOI":"10.1097\/MD.0000000000018040","volume":"98","author":"X Li","year":"2019","unstructured":"Li X, Shu K, Wang Z, Ding D. Prognostic significance of KIF2A and KIF20A expression in human cancer: a systematic review and meta-analysis. Medicine. 2019;98:e18040.","journal-title":"Medicine"},{"key":"8467_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03118-4","volume":"19","author":"G Li","year":"2021","unstructured":"Li G, Lan Q. Bioinformatics analysis reveals a stem cell-expressed circ-Serpine2-mediated miRNA-mRNA regulatory subnetwork in the malignant progression of glioma. J Transl Med. 2021;19:444.","journal-title":"J Transl Med"},{"key":"8467_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217105","volume":"598","author":"S Chen","year":"2024","unstructured":"Chen S, Zhao L, Liu J, Han P, Jiang W, Liu Y, et al. Inhibition of KIF20A enhances the immunotherapeutic effect of hepatocellular carcinoma by enhancing c-Myc ubiquitination. Cancer Lett. 2024;598:217105.","journal-title":"Cancer Lett"},{"key":"8467_CR22","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1038\/s41418-018-0242-0","volume":"26","author":"X Ding","year":"2019","unstructured":"Ding X, Jia X, Wang C, Xu J, Gao SJ, Lu C. A DHX9-lncRNA-MDM2 interaction regulates cell invasion and angiogenesis of cervical cancer. Cell Death Differ. 2019;26:1750\u201365.","journal-title":"Cell Death Differ"},{"key":"8467_CR23","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.7150\/ijbs.60628","volume":"17","author":"Y Liu","year":"2021","unstructured":"Liu Y, Xu S, Huang Y, Liu S, Xu Z, Wei M, et al. MARCH6 promotes papillary thyroid cancer development by destabilizing DHX9. Int J Biol Sci. 2021;17:3401\u201312.","journal-title":"Int J Biol Sci"},{"key":"8467_CR24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41419-023-06016-3","volume":"14","author":"Y Sun","year":"2023","unstructured":"Sun Y, Zhang H, Ma R, Guo X, Zhang G, Liu S, et al. ETS-1-activated LINC01016 over-expression promotes tumor progression via suppression of RFFL-mediated DHX9 ubiquitination degradation in breast cancers. Cell Death Dis. 2023;14:507.","journal-title":"Cell Death Dis"},{"key":"8467_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47235-2","volume":"15","author":"X Ren","year":"2024","unstructured":"Ren X, Liu Q, Zhou P, Zhou T, Wang D, Mei Q, et al. DHX9 maintains epithelial homeostasis by restraining R-loop-mediated genomic instability in intestinal stem cells. Nat Commun. 2024;15:3080.","journal-title":"Nat Commun"},{"key":"8467_CR26","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.7150\/ijbs.80873","volume":"19","author":"X Jiang","year":"2023","unstructured":"Jiang X, Zhang Y, Yuan Y, Jin Z, Zhai H, Liu B, et al. LncRNA GSCAR promotes glioma stem cell maintenance via stabilizing SOX2 expression. Int J Biol Sci. 2023;19:1681\u201397.","journal-title":"Int J Biol Sci"},{"key":"8467_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semcancer.2019.08.007","volume":"67","author":"D Novak","year":"2020","unstructured":"Novak D, H\u00fcser L, Elton JJ, Umansky V, Altevogt P, Utikal J. SOX2 in development and cancer biology. Semin Cancer Biol. 2020;67:74\u201382.","journal-title":"Semin Cancer Biol"},{"key":"8467_CR28","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1158\/0008-5472.CAN-14-2215","volume":"75","author":"CS Chien","year":"2015","unstructured":"Chien CS, Wang ML, Chu PY, Chang YL, Liu WH, Yu CC, et al. Lin28B\/Let-7 regulates expression of Oct4 and Sox2 and reprograms oral squamous cell carcinoma cells to a stem-like state. Cancer Res. 2015;75:2553\u201365.","journal-title":"Cancer Res"},{"key":"8467_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317\u201331.","journal-title":"Cell"},{"key":"8467_CR30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315541121","volume":"121","author":"H Li","year":"2024","unstructured":"Li H, Sun Y, Yao Y, Ke S, Zhang N, Xiong W, et al. USP8-governed GPX4 homeostasis orchestrates ferroptosis and cancer immunotherapy. Proc Natl Acad Sci USA. 2024;121:e2315541121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8467_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302953","volume":"10","author":"J Tang","year":"2023","unstructured":"Tang J, Long G, Hu K, Xiao D, Liu S, Xiao L, et al. Targeting USP8 inhibits O-GlcNAcylation of SLC7A11 to promote ferroptosis of hepatocellular carcinoma via stabilization of OGT. Adv Sci. 2023;10:e2302953.","journal-title":"Adv Sci"},{"key":"8467_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12:599\u2013620.","journal-title":"Protein Cell"},{"key":"8467_CR33","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.tcb.2023.05.003","volume":"33","author":"LE Pope","year":"2023","unstructured":"Pope LE, Dixon SJ. Regulation of ferroptosis by lipid metabolism. Trends Cell Biol. 2023;33:1077\u201387.","journal-title":"Trends Cell Biol"},{"key":"8467_CR34","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.7150\/thno.19988","volume":"7","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Mao C, Yang R, Yan B, Shi Y, Liu X, et al. EGLN1\/c-Myc induced lymphoid-specific helicase inhibits ferroptosis through lipid metabolic gene expression changes. Theranostics. 2017;7:3293\u2013305.","journal-title":"Theranostics"},{"key":"8467_CR35","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1158\/0008-5472.CAN-21-0567","volume":"81","author":"X Wang","year":"2021","unstructured":"Wang X, Chen Y, Wang X, Tian H, Wang Y, Jin J, et al. Stem cell factor SOX2 confers ferroptosis resistance in lung cancer via upregulation of SLC7A11. Cancer Res. 2021;81:5217\u201329.","journal-title":"Cancer Res"},{"key":"8467_CR36","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.cub.2020.04.081","volume":"30","author":"IE Adriaans","year":"2020","unstructured":"Adriaans IE, Hooikaas PJ, Aher A, Vromans MJM, van Es RM, Grigoriev I, et al. MKLP2 is a motile kinesin that transports the chromosomal passenger complex during anaphase. Curr Biol. 2020;30:2628\u201337.e9.","journal-title":"Curr Biol"},{"key":"8467_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nrm1552","volume":"6","author":"A Ciechanover","year":"2005","unstructured":"Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol. 2005;6:79\u201387.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8467_CR38","doi-asserted-by":"publisher","first-page":"8832","DOI":"10.1039\/D2CS00624C","volume":"51","author":"Y Ding","year":"2022","unstructured":"Ding Y, Xing D, Fei Y, Lu B. Emerging degrader technologies engaging lysosomal pathways. Chem Soc Rev. 2022;51:8832\u201376.","journal-title":"Chem Soc Rev"},{"key":"8467_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01877-w","volume":"22","author":"Z Zeng","year":"2023","unstructured":"Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer. Mol Cancer. 2023;22:172.","journal-title":"Mol Cancer"},{"key":"8467_CR40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1073\/pnas.0810956106","volume":"106","author":"A Dubrovska","year":"2009","unstructured":"Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garc\u00eda-Echeverr\u00eda C, et al. The role of PTEN\/Akt\/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA. 2009;106:268\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8467_CR41","doi-asserted-by":"publisher","first-page":"31189","DOI":"10.1073\/pnas.2017152117","volume":"117","author":"J Yi","year":"2020","unstructured":"Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci USA. 2020;117:31189\u201397.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8467_CR42","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jhep.2022.01.009","volume":"76","author":"M Yang","year":"2022","unstructured":"Yang M, Wu X, Hu J, Wang Y, Wang Y, Zhang L, et al. COMMD10 inhibits HIF1\u03b1\/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma. J Hepatol. 2022;76:1138\u201350.","journal-title":"J Hepatol"},{"key":"8467_CR43","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.numecd.2021.10.017","volume":"32","author":"JK Zhang","year":"2022","unstructured":"Zhang JK, Zhang Z, Guo ZA, Fu Y, Chen XJ, Chen WJ, et al. The BMSC-derived exosomal lncRNA Mir9-3hg suppresses cardiomyocyte ferroptosis in ischemia-reperfusion mice via the Pum2\/PRDX6 axis. Nutr Metab Cardiovasc Dis. 2022;32:515\u201327.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"8467_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40518-0","volume":"14","author":"Y Xue","year":"2023","unstructured":"Xue Y, Lu F, Chang Z, Li J, Gao Y, Zhou J, et al. Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade. Nat Commun. 2023;14:4758.","journal-title":"Nat Commun"},{"key":"8467_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-021-00304-3","volume":"10","author":"X Yang","year":"2021","unstructured":"Yang X, Liu J, Wang C, Cheng KK, Xu H, Li Q, et al. miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities. Oncogenesis. 2021;10:15.","journal-title":"Oncogenesis"},{"key":"8467_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103419","volume":"78","author":"K Wang","year":"2024","unstructured":"Wang K, Zhang X, Fan Y, Zhou L, Duan Y, Li S, et al. Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRAS(G12C) inhibitor resistant tumors. Redox Biol. 2024;78:103419.","journal-title":"Redox Biol"},{"key":"8467_CR47","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1158\/1535-7163.MCT-10-0574","volume":"10","author":"GC Fletcher","year":"2011","unstructured":"Fletcher GC, Brokx RD, Denny TA, Hembrough TA, Plum SM, Fogler WE, et al. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther. 2011;10:126\u201337.","journal-title":"Mol Cancer Ther"},{"key":"8467_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.879233","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen S. Glioma subtypes based on the activity changes of immunologic and hallmark gene sets in cancer. Front Endocrinol. 2022;13:879233.","journal-title":"Front Endocrinol"},{"key":"8467_CR49","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1038\/s41388-022-02307-9","volume":"41","author":"VA Copello","year":"2022","unstructured":"Copello VA, Burnstein KL. The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor. Oncogene. 2022;41:2824\u201332.","journal-title":"Oncogene"},{"key":"8467_CR50","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1080\/15548627.2024.2319901","volume":"20","author":"X Chen","year":"2024","unstructured":"Chen X, Tsvetkov AS, Shen HM, Isidoro C, Ktistakis NT, Linkermann A, et al. International consensus guidelines for the definition, detection, and interpretation of autophagy-dependent ferroptosis. Autophagy. 2024;20:1213\u201346.","journal-title":"Autophagy"},{"key":"8467_CR51","doi-asserted-by":"crossref","unstructured":"Khongkow P, Gomes AR, Gong C, Man EPS, Tsang JWH, Zhao F, et al. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene. 2016;35:990\u20131002.","DOI":"10.1038\/onc.2015.152"},{"key":"8467_CR52","doi-asserted-by":"publisher","first-page":"13515","DOI":"10.18632\/aging.202774","volume":"13","author":"C Yang","year":"2021","unstructured":"Yang C, Zhang Y, Lin S, Liu Y, Li W. Suppressing the KIF20A\/NUAK1\/Nrf2\/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin. Aging. 2021;13:13515\u201334.","journal-title":"Aging"},{"key":"8467_CR53","doi-asserted-by":"crossref","unstructured":"Daigo K, Takano A, Thang PM, Yoshitake Y, Shinohara M, Tohnai I, et al. Characterization of KIF11 as a novel prognostic biomarker and therapeutic target for oral cancer. Int J Oncol. 2018;52:155\u201365.","DOI":"10.3892\/ijo.2017.4181"},{"key":"8467_CR54","doi-asserted-by":"publisher","first-page":"e85951","DOI":"10.1371\/journal.pone.0085951","volume":"8","author":"Y Minakawa","year":"2013","unstructured":"Minakawa Y, Kasamatsu A, Koike H, Higo M, Nakashima D, Kouzu Y, et al. Kinesin family member 4A: a potential predictor for progression of human oral cancer. PLoS ONE. 2013;8:e85951.","journal-title":"PLoS ONE"},{"key":"8467_CR55","first-page":"26","volume":"3","author":"I Miyamoto","year":"2015","unstructured":"Miyamoto I, Kasamatsu A, Yamatoji M, Nakashima D, Saito K, Higo M, et al. Kinesin family member 14 in human oral cancer: a potential biomarker for tumoral growth. Biochem Biophys Rep. 2015;3:26\u201331.","journal-title":"Biochem Biophys Rep"},{"key":"8467_CR56","first-page":"2202","volume":"19","author":"ZY Li","year":"2019","unstructured":"Li ZY, Wang ZX, Li CC. Kinesin family member 20B regulates tongue cancer progression by promoting cell proliferation. Mol Med Rep. 2019;19:2202\u201310.","journal-title":"Mol Med Rep"},{"key":"8467_CR57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.oraloncology.2009.11.003","volume":"46","author":"CQ Wang","year":"2010","unstructured":"Wang CQ, Qu X, Zhang XY, Zhou CJ, Liu GX, Dong ZQ, et al. Overexpression of Kif2a promotes the progression and metastasis of squamous cell carcinoma of the oral tongue. Oral Oncol. 2010;46:65\u20139.","journal-title":"Oral Oncol"},{"key":"8467_CR58","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2174\/0115665232308821240826075513","volume":"25","author":"L Qi","year":"2025","unstructured":"Qi L, Tan Y, Zhou Y, Dong Y, Yang X, Chang S, et al. Proteogenomic identification and analysis of KIF5B as a prognostic signature for hepatocellular carcinoma. Current Gene Ther. 2025;25:532\u201345.","journal-title":"Current Gene Ther"},{"key":"8467_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.710","volume":"5","author":"TC Dakal","year":"2024","unstructured":"Dakal TC, Bhushan R, Xu C, Gadi BR, Cameotra SS, Yadav V, et al. Intricate relationship between cancer stemness, metastasis, and drug resistance. MedComm. 2024;5:e710.","journal-title":"MedComm"},{"key":"8467_CR60","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","volume":"31","author":"J-J Loh","year":"2024","unstructured":"Loh J-J, Ma S. Hallmarks of cancer stemness. Cell Stem Cell. 2024;31:617\u201339.","journal-title":"Cell Stem Cell"},{"key":"8467_CR61","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.3892\/ijo.2017.3955","volume":"50","author":"Y Fujiwara","year":"2017","unstructured":"Fujiwara Y, Okada K, Omori T, Sugimura K, Miyata H, Ohue M, et al. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017;50:1655\u201362.","journal-title":"Int J Oncol"},{"key":"8467_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.566","volume":"6","author":"E Singer","year":"2015","unstructured":"Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, et al. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis. 2015;6:e1601.","journal-title":"Cell Death Dis"},{"key":"8467_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41420-023-01323-2","volume":"9","author":"K Wu","year":"2023","unstructured":"Wu K, Zhang Y, Liu Y, Li Q, Chen Y, Chen J, et al. Phosphorylation of UHRF2 affects malignant phenotypes of HCC and HBV replication by blocking DHX9 ubiquitylation. Cell Death Discov. 2023;9:27.","journal-title":"Cell Death Discov"},{"key":"8467_CR64","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/hep.31062","volume":"72","author":"Z Hu","year":"2020","unstructured":"Hu Z, Dong L, Li S, Li Z, Qiao Y, Li Y, et al. Splicing regulator p54nrb \/non-POU domain-containing octamer-binding protein enhances carcinogenesis through oncogenic isoform switch of MYC box-dependent interacting protein 1 in hepatocellular carcinoma. Hepatology. 2020;72:548\u201368.","journal-title":"Hepatology"},{"key":"8467_CR65","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1038\/s41388-024-03126-w","volume":"43","author":"S Huang","year":"2024","unstructured":"Huang S, Hu J, Hu M, Hou Y, Zhang B, Liu J, et al. Cooperation between SIX1 and DHX9 transcriptionally regulates integrin-focal adhesion signaling mediated metastasis and sunitinib resistance in KIRC. Oncogene. 2024;43:2951\u201369.","journal-title":"Oncogene"},{"key":"8467_CR66","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/0008-5472.CAN-24-0397","volume":"85","author":"J Castro","year":"2025","unstructured":"Castro J, Daniels MH, Brennan D, Johnston B, Gotur D, Lee Y-T, et al. A potent, selective, small-molecule inhibitor of DHX9 abrogates proliferation of microsatellite instable cancers with deficient mismatch repair. Cancer Res. 2025;85:758\u201376.","journal-title":"Cancer Res"},{"key":"8467_CR67","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1158\/0008-5472.CAN-23-1908","volume":"84","author":"T-T Huang","year":"2024","unstructured":"Huang T-T, Chiang C-Y, Nair JR, Wilson KM, Cheng K, Lee J-M. AKT1 interacts with DHX9 to mitigate R loop-induced replication stress in ovarian cancer. Cancer Res. 2024;84:887\u2013904.","journal-title":"Cancer Res"},{"key":"8467_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101111","volume":"76","author":"K-L Chen","year":"2024","unstructured":"Chen K-L, Huang S-W, Yao J-J, He S-W, Gong S, Tan X-R, et al. LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein. Drug Resist Update. 2024;76:101111.","journal-title":"Drug Resist Update"},{"key":"8467_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105443","volume":"165","author":"M Alomari","year":"2021","unstructured":"Alomari M. TRIM21 - A potential novel therapeutic target in cancer. Pharmacol Res. 2021;165:105443.","journal-title":"Pharmacol Res"},{"key":"8467_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-03143-x","volume":"23","author":"C-H Hsu","year":"2023","unstructured":"Hsu C-H, Yu Y-L. The interconnected roles of TRIM21\/Ro52 in systemic lupus erythematosus, primary Sj\u00f6gren\u2019s syndrome, cancers, and cancer metabolism. Cancer Cell Int. 2023;23:289.","journal-title":"Cancer Cell Int"},{"key":"8467_CR71","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1080\/15548627.2022.2164427","volume":"19","author":"C Yang","year":"2023","unstructured":"Yang C, Wang Z, Kang Y, Yi Q, Wang T, Bai Y, et al. Stress granule homeostasis is modulated by TRIM21-mediated ubiquitination of G3BP1 and autophagy-dependent elimination of stress granules. Autophagy. 2023;19:1934\u201351.","journal-title":"Autophagy"},{"key":"8467_CR72","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/cac2.12386","volume":"43","author":"L Zhang","year":"2023","unstructured":"Zhang L, Li Q, Yang J, Xu P, Xuan Z, Xu J, et al. Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination\/degradation of STAT1 in a GTP binding-dependent modality. Cancer Commun. 2023;43:123\u201349.","journal-title":"Cancer Commun"},{"key":"8467_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404476","volume":"11","author":"J Li","year":"2024","unstructured":"Li J, Wang Y, Wang Z, Wei Y, Diao P, Wu Y, et al. Super-enhancer driven LIF\/LIFR-STAT3-SOX2 regulatory feedback loop promotes cancer stemness in head and neck squamous cell carcinoma. Adv Sci. 2024;11:e2404476.","journal-title":"Adv Sci"},{"key":"8467_CR74","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2019.09.011","volume":"61","author":"AWY Chai","year":"2020","unstructured":"Chai AWY, Lim KP, Cheong SC. Translational genomics and recent advances in oral squamous cell carcinoma. Semin Cancer Biol. 2020;61:71\u201383.","journal-title":"Semin Cancer Biol"},{"key":"8467_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13046-023-02623-2","volume":"42","author":"K Fang","year":"2023","unstructured":"Fang K, Sun M, Leng Z, Chu Y, Zhao Z, Li Z, et al. Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia. J Exp Clin Cancer Res. 2023;42:73.","journal-title":"J Exp Clin Cancer Res"},{"key":"8467_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-1014-y","volume":"20","author":"JR Diamond","year":"2018","unstructured":"Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, et al. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018;20:82.","journal-title":"Breast Cancer Res"},{"key":"8467_CR77","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1634\/theoncologist.2020-0093","volume":"25","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Mayer R, Venook AP, O\u2019Neill AF, Beg MS, LaQuaglia M, et al. Phase II multicenter, open-label study of oral ENMD-2076 for the treatment of patients with advanced fibrolamellar carcinoma. Oncologist. 2020;25:e1837\u2013e45.","journal-title":"Oncologist"},{"key":"8467_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43222-6","volume":"9","author":"Z Veitch","year":"2019","unstructured":"Veitch Z, Zer A, Loong H, Salah S, Masood M, Gupta A, et al. A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS). Sci Rep. 2019;9:7390.","journal-title":"Sci Rep"},{"key":"8467_CR79","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2012.07.020","volume":"49","author":"UA Matulonis","year":"2013","unstructured":"Matulonis UA, Lee J, Lasonde B, Tew WP, Yehwalashet A, Matei D, et al. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer. 2013;49:121\u201331.","journal-title":"Eur J Cancer"},{"key":"8467_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1402514","volume":"15","author":"R Chen","year":"2024","unstructured":"Chen R, Zhu S, Zhao R, Liu W, Jin L, Ren X, et al. Targeting ferroptosis as a potential strategy to overcome the resistance of cisplatin in oral squamous cell carcinoma. Front Pharmacol. 2024;15:1402514.","journal-title":"Front Pharmacol"},{"key":"8467_CR81","doi-asserted-by":"crossref","unstructured":"Meng X, Lou Q-Y, Yang W-Y, Wang Y-R, Chen R, Wang L, et al. The role of non-coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential. Cancer Commun. 2021;41:981\u20131006.","DOI":"10.1002\/cac2.12194"},{"key":"8467_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.449","volume":"4","author":"J Huang","year":"2023","unstructured":"Huang J, Liang L, Jiang S, Liu Y, He H, Sun X, et al. BDH1-mediated LRRC31 regulation dependent on histone lysine \u03b2-hydroxybutyrylation to promote lung adenocarcinoma progression. MedComm. 2023;4:e449.","journal-title":"MedComm"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08467-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08467-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08467-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:21:42Z","timestamp":1771564902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08467-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8467"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08467-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Human tumor and adjacent non-tumor specimens were obtained from the Institute of Cancer Research, Hunan Normal University. The collection and use of clinical samples were approved by the Ethics Committee of Hunan Normal University, and written informed consent was obtained from all participating patients or their legally authorized representatives, in accordance with the Declaration of Helsinki. All animal experiments, including nude mouse xenograft assays, were conducted in accordance with institutional guidelines, under protocols reviewed and approved by the Ethics Committee of Hunan Normal University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"218"}}